Cargando…
Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions i...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853626/ https://www.ncbi.nlm.nih.gov/pubmed/35157511 http://dx.doi.org/10.1200/GO.21.00244 |
_version_ | 1784653272644059136 |
---|---|
author | Joseph, Adedayo Olatosi, Bankole Haider, Mohammad Rifat Adegboyega, Bolanle C. Lasebikan, Nwamaka N. Aliyu, Usman M. Ali-Gombe, Musa Jimoh, Mutiu A. Biyi-Olutunde, Olusegun Abayomi Awofeso, Opeyemi Fatiregun, Omolara Aminat Oboh, Evaristus Oseiwe Nwachukwu, Emmanuella Zubairu, Ismail H. Otene, Samuel A. Iyare, Oluwatoyin I. Andero, Temitope Musbau, Alabi Babatunde Ajose, Azeezat Onitilo, Adedayo A. |
author_facet | Joseph, Adedayo Olatosi, Bankole Haider, Mohammad Rifat Adegboyega, Bolanle C. Lasebikan, Nwamaka N. Aliyu, Usman M. Ali-Gombe, Musa Jimoh, Mutiu A. Biyi-Olutunde, Olusegun Abayomi Awofeso, Opeyemi Fatiregun, Omolara Aminat Oboh, Evaristus Oseiwe Nwachukwu, Emmanuella Zubairu, Ismail H. Otene, Samuel A. Iyare, Oluwatoyin I. Andero, Temitope Musbau, Alabi Babatunde Ajose, Azeezat Onitilo, Adedayo A. |
author_sort | Joseph, Adedayo |
collection | PubMed |
description | Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS: Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS: Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION: This study investigated COVID-19–influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era. |
format | Online Article Text |
id | pubmed-8853626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-88536262022-02-18 Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria Joseph, Adedayo Olatosi, Bankole Haider, Mohammad Rifat Adegboyega, Bolanle C. Lasebikan, Nwamaka N. Aliyu, Usman M. Ali-Gombe, Musa Jimoh, Mutiu A. Biyi-Olutunde, Olusegun Abayomi Awofeso, Opeyemi Fatiregun, Omolara Aminat Oboh, Evaristus Oseiwe Nwachukwu, Emmanuella Zubairu, Ismail H. Otene, Samuel A. Iyare, Oluwatoyin I. Andero, Temitope Musbau, Alabi Babatunde Ajose, Azeezat Onitilo, Adedayo A. JCO Glob Oncol ORIGINAL REPORTS Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS: Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS: Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION: This study investigated COVID-19–influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era. Wolters Kluwer Health 2022-02-14 /pmc/articles/PMC8853626/ /pubmed/35157511 http://dx.doi.org/10.1200/GO.21.00244 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | ORIGINAL REPORTS Joseph, Adedayo Olatosi, Bankole Haider, Mohammad Rifat Adegboyega, Bolanle C. Lasebikan, Nwamaka N. Aliyu, Usman M. Ali-Gombe, Musa Jimoh, Mutiu A. Biyi-Olutunde, Olusegun Abayomi Awofeso, Opeyemi Fatiregun, Omolara Aminat Oboh, Evaristus Oseiwe Nwachukwu, Emmanuella Zubairu, Ismail H. Otene, Samuel A. Iyare, Oluwatoyin I. Andero, Temitope Musbau, Alabi Babatunde Ajose, Azeezat Onitilo, Adedayo A. Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title | Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title_full | Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title_fullStr | Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title_full_unstemmed | Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title_short | Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria |
title_sort | patient's perspective on the impact of covid-19 on cancer treatment in nigeria |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853626/ https://www.ncbi.nlm.nih.gov/pubmed/35157511 http://dx.doi.org/10.1200/GO.21.00244 |
work_keys_str_mv | AT josephadedayo patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT olatosibankole patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT haidermohammadrifat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT adegboyegabolanlec patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT lasebikannwamakan patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT aliyuusmanm patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT aligombemusa patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT jimohmutiua patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT biyiolutundeolusegunabayomi patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT awofesoopeyemi patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT fatiregunomolaraaminat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT obohevaristusoseiwe patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT nwachukwuemmanuella patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT zubairuismailh patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT otenesamuela patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT iyareoluwatoyini patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT anderotemitope patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT musbaualabibabatunde patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT ajoseazeezat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria AT onitiloadedayoa patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria |